A win for the biotech Vaxcyte in an early-stage trial of its experimental pneumococcal disease vaccine is worrying news for ...

(Bloomberg) -- Merck & Co. won US approval for a pneumococcal vaccine that threatens to unseat one of Pfizer Inc.’s biggest franchises. Called Capvaxive, Merck’s vaccine is approved to prevent ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

FDA approval of Merck’s new pneumococcal vaccine, Capvaxive, tees up a new challenge to one of Pfizer’s most important products.

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to ...

As U.S. regulatory uncertainty swirls around the vaccine space and health care in general, Vaxcyte Inc. stands poised for a ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

However, Pfizer has two other vaccines on the market that generate more than $1 billion annually: pneumococcal vaccine Prevnar 20 and respiratory syncytial virus (RSV) vaccine Abrysvo. Pfizer's ...

In 2010 Pfizer released a new blend called Prevnar ... and its new column with the check mark in place: pneumococcal conjugate vaccine. If the inoculation does its job, Jannat will be protected ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Following the merger with Wyeth several years ago, Pfizer has a much stronger position in the vaccine industry with pneumococcal vaccine Prevnar. Vaccines tend to be more resistant to generic ...